Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

ProMIS Neurosciences Inc.

PMN · Nasdaq · CIK 0001374339 · Healthcare · Biotechnology

INSIDER SIGNAL

51.5 / 100

2 buyers · 2 purchase transaction lines · $75.6K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+6.6 / 25
Role+18.0 / 20
Recency+2.9 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Chief Development Officer

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION60%Largest buyer: Kirwin Patrick D. · $45.3K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-04-22–2026-04-22

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Kirwin Patrick D.Director
●
Kaplan JohanneChief Development Officer
●
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

51.5 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 51.8
  2. 51.7
  3. 51.6
  4. 51.5
  5. 51.5

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

8Purchases
0Sales
5Other Form 4 lines
11SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-28.3%
3M
-24.9%
6M
-23.7%
12M
-32.6%

Volatility & liquidity

Volatility
144.0%
Beta
—
Avg daily value
USD 793,496

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
238,584
Previous report
240,000
Avg daily volume
33,526
Days to cover
7.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-05Kaplan JohannePurchase (P)Common Shares2,280USD 13.30USD 30,324SEC filing ↗
2026-04-22Kirwin Patrick D.Purchase (P)Common Shares4,000USD 11.33USD 45,320SEC filing ↗
2026-03-05Williams EugenePurchase (P)Common Shares2,000USD 24.40USD 48,800SEC filing ↗
2026-03-04Williams EugenePurchase (P)Common Shares2,000USD 24.00USD 48,000SEC filing ↗
2026-03-03Williams EugenePurchase (P)Common Shares1,000USD 21.89USD 21,890SEC filing ↗
2026-03-02Williams EugenePurchase (P)Common Shares1,000USD 22.53USD 22,530SEC filing ↗
2026-02-19Kaplan JohannePurchase (P)Common Shares1,629USD 15.35USD 25,005SEC filing ↗
2026-02-03ABG Management Ltd.; Alex Slanix Paul; Ally Bridge Group (NY) LLC; Ally Bridge MedAlpha Master Fund L.P.; Yu FanPurchase (P)Common Shares700,741USD 12.13USD 8,499,988SEC filing ↗
2025-10-03Milbury Max A.Purchase (P)Common Shares30,392USD 0.49USD 14,892SEC filing ↗
2025-02-10Cashman NeilPurchase (P)Common Shares15,000USD 0.97USD 14,550SEC filing ↗
2024-09-24Shafmaster Madge K.Purchase (P)Common Shares70,000USD 1.30USD 91,000SEC filing ↗
2024-09-23Shafmaster Madge K.Purchase (P)Common Shares70,000USD 1.28USD 89,600SEC filing ↗
2024-09-20Shafmaster Madge K.Purchase (P)Common Shares60,000USD 1.25USD 75,000SEC filing ↗
2024-09-17GORDON MICHAEL SPurchase (P)Common Shares, no par value16,292USD 1.40USD 22,809SEC filing ↗
2024-09-16GORDON MICHAEL SPurchase (P)Common Shares, no par value76,931USD 1.22USD 93,856SEC filing ↗

Form 4 evidence

13 transaction lines in the latest 365-day window; 50 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-05Kaplan JohannePurchase (P)Common Shares2,280USD 13.30USD 30,324SEC filing ↗
2026-04-22Kirwin Patrick D.Purchase (P)Common Shares4,000USD 11.33USD 45,320SEC filing ↗
2026-03-05Williams EugenePurchase (P)Common Shares2,000USD 24.40USD 48,800SEC filing ↗
Show recent Form 4 evidence (13 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-05Kaplan JohannePurchase (P)Common Shares2,280USD 13.30USD 30,324SEC filing ↗
2026-04-22Kirwin Patrick D.Purchase (P)Common Shares4,000USD 11.33USD 45,320SEC filing ↗
2026-03-05Williams EugenePurchase (P)Common Shares2,000USD 24.40USD 48,800SEC filing ↗
2026-03-04Williams EugenePurchase (P)Common Shares2,000USD 24.00USD 48,000SEC filing ↗
2026-03-03Williams EugenePurchase (P)Common Shares1,000USD 21.89USD 21,890SEC filing ↗
2026-03-02Williams EugenePurchase (P)Common Shares1,000USD 22.53USD 22,530SEC filing ↗
2026-02-19Kaplan JohannePurchase (P)Common Shares1,629USD 15.35USD 25,005SEC filing ↗
2026-02-03Warma Neil KAward / grant (A)Common Shares6,183USD 12.13USD 75,000SEC filing ↗
2026-02-03Milbury Max A.Award / grant (A)Common Shares6,595USD 12.13USD 79,997SEC filing ↗
2026-02-03Kirwin Patrick D.Award / grant (A)Common Shares3,050USD 12.13USD 36,996SEC filing ↗
2026-02-03Kaplan JohanneAward / grant (A)Common Shares2,060USD 12.13USD 24,988SEC filing ↗
2026-02-03Cashman NeilAward / grant (A)Common Shares4,122USD 12.13USD 50,000SEC filing ↗
2026-02-03ABG Management Ltd.; Alex Slanix Paul; Ally Bridge Group (NY) LLC; Ally Bridge MedAlpha Master Fund L.P.; Yu FanPurchase (P)Common Shares700,741USD 12.13USD 8,499,988SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerPMN
CIK0001374339
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history50 transaction lines from 2022-07-11 to 2026-08-05
31 P purchase lines · 1 S sale lines · 18 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.